Sevirumab (MSL-109) is a human monoclonal antibody for the treatment of infections with cytomegalovirus in patients with AIDS.[1][2]
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Human |
| Target | CMV |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| ChEMBL | |
| (verify) | |
References
edit- ^ Borucki MJ, Spritzler J, Asmuth DM, Gnann J, Hirsch MS, Nokta M, et al. (November 2004). "A phase II, double-masked, randomized, placebo-controlled evaluation of a human monoclonal anti-Cytomegalovirus antibody (MSL-109) in combination with standard therapy versus standard therapy alone in the treatment of AIDS patients with Cytomegalovirus retinitis". Antiviral Research. 64 (2): 103–11. doi:10.1016/j.antiviral.2004.06.012. PMID 15498605.
- ^ Clinical trial number NCT00000836 for "A Phase II/III Trial of Human Anti-CMV Monoclonal Antibody MSL 109 (MACRT)" at ClinicalTrials.gov
 | This antiinfective drug article is a stub. You can help Wikipedia by expanding it. |
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |